Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
about
Botulinum Toxin A for Bladder Pain Syndrome/Interstitial CystitisBotulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of ActionTreatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee PainTreatment of Chronic Migraine with Focus on Botulinum NeurotoxinsBotulinum Toxin as a Pain Killer: Players and Actions in AntinociceptionUrothelial signaling.Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder.Intravesical botulinum toxin for lower urinary tract dysfunctionPreferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestineStem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold?Therapeutic use of botulinum toxin in migraine: mechanisms of action.Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial.Role of peptidergic nerve terminals in the skin: reversal of thermal sensation by calcitonin gene-related peptide in TRPV1-depleted neuropathy.Botulinum toxin therapy for osteoarticular pain: an evidence-based reviewNew insights into the pharmacology of the bladderPreclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex.Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle.Structural and Functional Interactions between Transient Receptor Potential Vanilloid Subfamily 1 and Botulinum Neurotoxin Serotype A.O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain SyndromeThe effect of intra-articular botulinum toxin A on substance P, prostaglandin E2, and tumor necrosis factor alpha in the canine osteoarthritic joint.Botulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladderPatients With Neurogenic Lower Urinary Tract Dysfunction Following Spinal Cord Injury Are at Increased Risk of Developing Type 2 Diabetes Mellitus: A Population-Based Cohort Study.Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderAdverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?Botulinum toxin type A for neuropathic pain in patients with spinal cord injury.New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Nonoperative treatment approach to knee osteoarthritis in the master athlete.Botulinum toxin type a therapy in migraine: preclinical and clinical trials.Use of botulinum toxin in musculoskeletal pain.Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.Treatment of refractory pain with botulinum toxins--an evidence-based review.Botulinum neurotoxin for pain management: insights from animal models.Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.Intravesical treatments of bladder pain syndrome/interstitial cystitis.Treatment of lower urinary tract symptoms: agents for intraprostatic injection.An update on botulinum toxin A injections of trigger points for myofascial pain.Painful bladder syndrome: an update and review of current management strategies.Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
P2860
Q26744717-0AFFE2A8-ED28-48EA-A040-BD2F945AC853Q26750535-F0A107AC-2592-4CA7-9FE0-82A23B461E56Q26773579-241656FD-0BC3-472B-B814-205E4EE40F69Q26797317-899BFCC8-4C49-4B7F-8073-015D9CE94809Q26799906-F326F596-25E4-4C63-BF88-1BBE6FFF75DFQ28084583-8812C6C3-CC4C-4652-9636-D8A8FEEB7A04Q30440958-CD06751D-8946-4076-9712-A13E716C1B37Q33671401-1538CE59-76F0-4BC5-B2C1-20C35DE9DB52Q33915263-D08CAAC9-F11C-4D65-BD2A-AAF4E82FE98FQ34167664-61544DD9-4EF3-40D2-9E6C-AA18E1BBD0E3Q34205889-BF1EA095-46CE-4456-A3E1-0BD0099E1932Q34253770-B06BA40B-E2B8-4779-9313-FB54D644096CQ34419654-D01D5BFA-76BC-460C-B1B6-2D443D15A219Q34479556-AB430DB0-F529-4265-B334-5CE68940002EQ34500724-8DFE9855-A960-403B-9373-6DD237F32496Q34554147-1835556C-0D17-43AA-8327-91613AB978DDQ34931019-D0202CE7-2DD2-446E-9D68-99E6739AD2AAQ35657577-CF4816C2-A19D-4D12-90FD-8ECF94F0ACAEQ35814877-131ED81D-EB0D-4C4B-A202-68969E5137AAQ35888886-6FF0614D-D6D5-4419-A442-E9AB0CEE8F05Q35996597-AFF1A8BC-D4BA-4C72-81C9-8DBEAE239D3BQ36317549-179D24CF-941C-407E-A546-F39040BC4F77Q36329632-AA90B174-9966-43EF-9E9D-F1E5E9887AE6Q36478281-63B11B74-38BD-4813-80D7-B651CA3699EEQ36573132-3AA2E47C-CC6D-45D1-ACF4-65B62BCCE0E9Q36735590-E9CD7A21-0630-45FD-AAF2-C35B65A3DD02Q36780108-372283EA-1FCC-4EC7-A65D-1B2335C62901Q36789948-98F83CCD-5A1E-4E54-9A41-52D481F0D3E6Q37417111-28AA1753-253B-4964-AF33-89786C49A3F0Q37631993-B27E378A-3CEF-484B-9166-7143F97B8DCDQ37671002-47E38EFD-21D9-429C-A358-192E59C0F77AQ37887644-D36115A2-409C-4878-8C4A-FD186510B937Q37940623-7E7A0881-AB74-4ADA-88EF-B8A8C76DC84AQ37954278-C1B278D1-540B-4807-B78C-9E92EAB98DFEQ37978568-C9D2B5B7-D50F-4C99-9316-8039E5951013Q38062822-83C5BB30-A871-4C2A-8059-5A2D8D9E7B2BQ38071100-995E129E-2413-478D-89C0-3684C28491D6Q38171394-5C8E9C13-515C-41D8-96CA-FEE7978F9A8AQ38175328-1E996804-1D54-491E-9B59-3566315AD470Q38210146-6DE2833A-D2C8-46F4-B104-5FF6B59E946A
P2860
Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@en
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@nl
type
label
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@en
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@nl
prefLabel
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@en
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@nl
P2093
P1433
P1476
Botulinum toxin type A inhibit ...... jury and chronic inflammation.
@en
P2093
Alvaro Lucioni
Daniel S McGehee
David E Rapp
Gregory T Bales
Sean P Cook
P2860
P304
P356
10.1111/J.1464-410X.2007.07312.X
P577
2008-02-01T00:00:00Z